Polycyclo Ring System Patents (Class 514/510)
-
Publication number: 20110105996Abstract: Provided herein are compositions and methods for preventing or reducing scar formation (e.g., hypertrophic scars). For example, provided herein are methods of administrating HMG-CoA-inhibiting agents for preventing or reducing scar formation.Type: ApplicationFiled: October 18, 2010Publication date: May 5, 2011Applicant: NORTHWESTERN UNIVERSITYInventors: Thomas A. Mustoe, Peter Kim, Jason Ko, Xianzhong Ding, Yanan Zhao
-
Publication number: 20110086070Abstract: The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions.Type: ApplicationFiled: September 26, 2008Publication date: April 14, 2011Inventors: Munish Talwar, Rahul Dabre, Ritesh Kapoor, Himanshu Verma, Nitin Jain, Girish Kumar Jain
-
Publication number: 20110082119Abstract: A highly safe and effective prophylactic/ameliorating or therapeutic agent for NACH and the method for using the same are provided. A prophylactic/ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ?3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.Type: ApplicationFiled: June 12, 2009Publication date: April 7, 2011Inventor: Takashi YANO
-
Publication number: 20110077251Abstract: The invention relates to 17? lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.Type: ApplicationFiled: August 16, 2010Publication date: March 31, 2011Inventors: Christophe Moinet, Bingcan Liu, Liliane Halab, Nathalie Turcotte, Real Denis, Carl Poisson, Paul Nguyen-Ba, Monica Bubenik, Laval Chan Chun Kong
-
Publication number: 20110077297Abstract: A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound (NVX-207), a related compound, or a pharmaceutically acceptable salt thereof to the mammal.Type: ApplicationFiled: May 28, 2009Publication date: March 31, 2011Applicant: NOVELIX PHARMACEUTICALS, INC.Inventor: Burkhard Jansen
-
Publication number: 20110070272Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.Type: ApplicationFiled: November 30, 2010Publication date: March 24, 2011Inventors: Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
-
Publication number: 20110071176Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.Type: ApplicationFiled: September 23, 2010Publication date: March 24, 2011Applicant: AMARIN PHARMA, INC.Inventor: Jonathan Rowe
-
Patent number: 7910623Abstract: A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.Type: GrantFiled: January 22, 2008Date of Patent: March 22, 2011Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Stephen P. Waters
-
Publication number: 20110065788Abstract: The invention relates to aqueous formulations containing (?)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.Type: ApplicationFiled: November 18, 2010Publication date: March 17, 2011Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Bernd Kühn, Antje Brück, Yoshifumi Katakawa, Masami Yasui
-
Patent number: 7906137Abstract: A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include ?-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N?-deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.Type: GrantFiled: May 21, 2004Date of Patent: March 15, 2011Assignee: Mediplex Corporation, KoreaInventors: Youngro Byun, Seulki Lee, Hyuntae Moon
-
Publication number: 20110052683Abstract: The present invention provides a pharmaceutical preparation comprising a prior-release compartment containing a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor as a pharmacologically active ingredient, and a delayed-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. The preparation of the present invention provides synergistic effects through combined administration of the non-dihydropyridine calcium channel blocker and the HMG-CoA reductase inhibitor, and induces the time-dependent absorption, metabolism and action mechanism of individual drugs through the controlled release thereof to avoid competitive antagonism between drugs, thus maximizing the effects of each pharmacologically active ingredient while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once a day.Type: ApplicationFiled: February 21, 2009Publication date: March 3, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Ja Seong Koo, Young Joo Lee, Seok Young Jang, Young Gwan Jo
-
Publication number: 20110054021Abstract: Novel calcilytic compounds and methods of using them are provided.Type: ApplicationFiled: September 30, 2010Publication date: March 3, 2011Inventors: ROBERT W. MARQUIS, LINDA N. CASILLAS, JOSHI M. RAMANJULU, JAMES FRANCIS CALLAHAN
-
Patent number: 7888355Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: GrantFiled: August 11, 2010Date of Patent: February 15, 2011Assignee: Burnham Institute for Medical ResearchInventors: Ze′ev A. Ronai, Anindita Bhoumik, Nicholas D. P. Cosford, Russell Dahl
-
Patent number: 7883714Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: GrantFiled: December 11, 2009Date of Patent: February 8, 2011Assignee: NicOx S.A.Inventors: Richard A. Earl, Maiko Ezawa, Xinqin Fang, David S. Garvey, Ricky D. Gaston, Subhash P. Khanapure, L. Gordon Letts, Chia-En Lin, Ramani R. Ranatunge, Stewart K. Richardson, Joseph D. Schroeder, Cheri A. Stevenson, Shiow-Jyi Wey
-
Patent number: 7883723Abstract: The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan since the water soluble chitosan itself can combined with DNA having a negative electric charge(?) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof. Therefore, a water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention can effectively envelope paclitaxel by introducing hydrophilic and hydrophobic groups in the position of highly reactive amine group of the water-soluble chitosan.Type: GrantFiled: May 13, 2005Date of Patent: February 8, 2011Inventors: Jae-Woon Nah, Teok Rae Jung, Mi-Kyeong Jang, Young-Il Jeong
-
Publication number: 20110028522Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.Type: ApplicationFiled: March 3, 2009Publication date: February 3, 2011Applicant: LUNA INNOVATIONS INCORPORATEDInventors: Christopher L. Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou, Darren K. MacFarland
-
Patent number: 7879904Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.Type: GrantFiled: June 2, 2010Date of Patent: February 1, 2011Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Publication number: 20110020414Abstract: An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one non-limiting illustration, the anti-aging composition contains about 1.0 vol % retinol, plantago lanceolata, hypericum perforatum leaf extract, phytosphingosine, leontopodium alpinum extract, glycyrriza glabra root extract, sambucus nigra flower extract, nordihydrognaiaretic acid, oleanolic acid, spiraea ulmaria flower extract, evodia rutaecarpa fruit extract, boswellia serrata extract, and additives.Type: ApplicationFiled: July 27, 2010Publication date: January 27, 2011Inventor: Audrey KUNIN
-
Publication number: 20110021508Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: ApplicationFiled: September 16, 2010Publication date: January 27, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventor: Daniel Alkon
-
Publication number: 20110009363Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: ApplicationFiled: May 10, 2010Publication date: January 13, 2011Inventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
-
Publication number: 20110009486Abstract: Disclosed herein are methods of treating pruritus in a subject in need thereof. A method of treating pruritus comprises administering a therapeutically effective amount of fullerenes to a subject in need thereof.Type: ApplicationFiled: March 3, 2009Publication date: January 13, 2011Applicant: Luna Innovations IncorporatedInventors: Christopher Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou
-
Publication number: 20110009485Abstract: A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.Type: ApplicationFiled: January 22, 2008Publication date: January 13, 2011Inventors: Samuel J. Danishefsky, Stephen P. Waters
-
Publication number: 20100305129Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Applicant: Burnham Institute for Medical ResearchInventors: Zéev A. Ronai, Anindita Bhoumik, Nicholas D.P. Cosford, Russell Dahl
-
Patent number: 7842716Abstract: The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of statins. In one embodiment, individuals who are at risk for vascular events, but have cholesterol levels (e.g., total cholesterol or Low Density Lipoprotein) in normal ranges, are treated with statins.Type: GrantFiled: March 29, 2004Date of Patent: November 30, 2010Assignee: HeartDrug Research, LLCInventor: Victor L. Serebruany
-
Publication number: 20100298138Abstract: The present invention relates to the use of aminoazoline and urea derivatives for com-bating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and veterinary composition comprising said compounds and to specific azoline and urea derivatives.Type: ApplicationFiled: May 23, 2008Publication date: November 25, 2010Applicant: BASF SEInventors: Christopher Koradin, Markus Kordes, Ernst Baumann, Ronan Le Vezouet, Deborah L. Culbertson
-
Publication number: 20100298367Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: ApplicationFiled: March 4, 2009Publication date: November 25, 2010Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
-
Publication number: 20100298200Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.Type: ApplicationFiled: May 22, 2009Publication date: November 25, 2010Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
-
Publication number: 20100273801Abstract: The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications.Type: ApplicationFiled: June 6, 2007Publication date: October 28, 2010Applicant: Valition teknillinen tutikimuskeskusInventors: Jari Yli-Kauhaluoma, Salme Koskimies, Sami Alakurtti, Taru Mäkelä, Päivi Tammela
-
Publication number: 20100273739Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.Type: ApplicationFiled: February 16, 2010Publication date: October 28, 2010Inventors: Wilhelm Amberg, Micheal Ochse, Udo Lange, Andreas King, Berthold Behl, Wilfried Hamberger, Maric Mezier, Charles W. Hutchins
-
Publication number: 20100255125Abstract: The invention relates to a process for cosmetic treatment, including the reduction of superficial and deep wrinkles, using ferutinine from Ferula spp extracts.Type: ApplicationFiled: June 16, 2010Publication date: October 7, 2010Applicant: INDENA S.P.A.Inventors: Ezio BOMBARDELLI, Gabriele FONTANA, Aldo CRISTONI, Enrico MERCALLI
-
Publication number: 20100240683Abstract: The present invention relates to a combination therapy for the treatment of cardiovascular disorders. More particularly, the invention relates to compositions combining long-chain optionally substituted amphipatic carboxylates (known as MEDICA drugs) and particularly, M16??, M16?? and M18??, with HMG-CoA reductase inhibitors (known as statins). The compositions of the invention may particularly be used for the treatment of cardiovascular disorders, for elevating HDL-cholesterol levels, decreasing non-HDL-cholesterol and particularly triglycerides, and decreasing insulin resistance in a subject suffering from Metabolic Syndrome or cardiovascular disorders. The invention further provides methods of treatment of such disorders using these combined compositions.Type: ApplicationFiled: February 26, 2008Publication date: September 23, 2010Applicant: Syndromex Ltd.Inventor: Jacob Bar-Tana
-
Publication number: 20100241059Abstract: A device for treating a skin condition is provided. The device comprises a delivery system for administering a composition to the skin disorder. The delivery system includes an electrode for delivering a composition to the skin of a person and a counter electrode. The device also includes a drainage system which includes a channel for removing material from a person's skin and a pump in communication with the channel The device further includes a control system for powering and controlling the electrode system.Type: ApplicationFiled: October 23, 2008Publication date: September 23, 2010Applicant: SKINTREET, LLCInventors: Marina Prushinskaya, Leonid Kaplan
-
Patent number: 7795306Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-?B for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-?B inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.Type: GrantFiled: March 1, 2007Date of Patent: September 14, 2010Inventors: Inderjit Kumar Dev, Ven Subbiah
-
Patent number: 7795305Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.Type: GrantFiled: October 10, 2008Date of Patent: September 14, 2010Assignees: Board of Regents, The University of Texas System, The Trustees of Dartmouth CollegeInventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn
-
Publication number: 20100221334Abstract: Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs (NSAIDs) and modified NSAIDs and leukotriene antagonists and methods for using such pharmaceutical compositions are provided herein. In a preffered embodiment naproxene 2-(methanesulfonyl)-ethyl ester is used in combination with Zileuton.Type: ApplicationFiled: July 18, 2008Publication date: September 2, 2010Inventor: Mitchell P. Fink
-
Patent number: 7776894Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.Type: GrantFiled: August 15, 2008Date of Patent: August 17, 2010Assignee: Burnham Institute for Medical ResearchInventors: Ze'ev A. Ronai, Anindita Bhoumik, Nicholas D. P. Cosford, Russell Dahl
-
Publication number: 20100190795Abstract: The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.Type: ApplicationFiled: June 6, 2007Publication date: July 29, 2010Applicant: Valtion Teknillinen tutkimuskeskusInventors: Jari Yli-Kauhaluoma, Sami Alakurtti, Jaana Minkkinen, Nina Sarcerdoti-Sierra, Charles L. Jaffe, Tuomo Heiska
-
Patent number: 7763651Abstract: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.Type: GrantFiled: August 1, 2006Date of Patent: July 27, 2010Assignee: Allergan, Inc.Inventors: George R. Ehring, Joseph S. Adorante, John E. Donello, Larry A. Wheeler, Thomas Malone
-
Publication number: 20100178324Abstract: The present invention includes methods of making and methods of using peptidomimetics compositions that mimic ?-helical BH3 sequences in cells. The peptidomimetics can be used to mimic ?-helical BH3 sequences and kill cancer cells.Type: ApplicationFiled: January 13, 2009Publication date: July 15, 2010Applicant: Board of Regents, The University SystemInventor: Jung-Mo Ahn
-
Publication number: 20100173989Abstract: The present invention provides an antiwrinkle agent and skin cosmetic composition having excellent alleviating effects on wrinkles appearing due to aging, and especially at exposed locations of skin, and a high degree of safety. The present invention relates to an antiwrinkle agent and skin cosmetic composition comprising a sclareol derivative represented by the following structural formula (1).Type: ApplicationFiled: July 9, 2009Publication date: July 8, 2010Inventors: Kyoko MIURA, Akinori Haratake, Syunsuke Yamazaki, Bunichi Okabe, Takeshi Ikemoto
-
Publication number: 20100173970Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.Type: ApplicationFiled: February 23, 2010Publication date: July 8, 2010Inventor: S. Bruce King
-
Publication number: 20100168231Abstract: The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea.Type: ApplicationFiled: January 5, 2010Publication date: July 1, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Laurent Lamy, Michel Rivier, Gérard Feraille
-
Publication number: 20100166670Abstract: The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of, normal leucocytic elastase or plasmin activity, in human or veterinary medicine. The invention further concerns the use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preparing a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.Type: ApplicationFiled: December 1, 2009Publication date: July 1, 2010Applicant: Hermann P. T. AmmonInventors: Hermann P.T. Ammon, Hasan Safayhi
-
Publication number: 20100167927Abstract: The invention relates to substituted amino-thiourea compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted amino-thiourea compounds, of their salts or of compositions comprising them for combating animal pests. Furthermore the invention relates also to methods of applying such compounds. The substituted amino-thiourea compounds are defined by the following formula (I): wherein A, B, R1, R2, R3, R4, R5.1, R5.2 and R6 are defined as in the description.Type: ApplicationFiled: May 13, 2008Publication date: July 1, 2010Applicant: BASF SEInventors: Christopher Koradin, Markus Kordes, Ernst Baumann, Ronan Le Vezouet, Deborah L. Culbertson
-
Publication number: 20100168004Abstract: The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells by providing HAART simultaneously. Compositions of the invention comprise an activator of latent HIV expression, such as prostratin, and an inhibitor of histone deacetylase, such as TSA. A surprising finding of this invention is that the inhibitor of the histone deacetylase synergizes the effect of prostratin thus, allowing administering to a patient a lower, non-toxic dose of prostratin.Type: ApplicationFiled: April 17, 2007Publication date: July 1, 2010Applicant: J. DAVID GLADATONE INSTITUTESInventors: Samuel A.F. Williams, Warner C. Greene
-
Patent number: 7745439Abstract: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.Type: GrantFiled: April 12, 2005Date of Patent: June 29, 2010Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Sun Mee Kim, Kil Woong Mo, Jae Mok Lee, Hye Jung Kang, Koun Ho Lee, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim
-
Patent number: 7741323Abstract: An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, R1 is C1-6 alkyl, C1-6 alkenyl, or C3-6 cycloalkyl, each of which is unsubstituted or substituted with one or more phenyl groups; R2 is H, CN, CO2Ra, CH2CO2Ra, CONRbRc, or phenyl; R3 is C1-6 alkyl, C3-6 cycloalkyl, naphthyl, phenyl, being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH2, NO2, ORa, phenyloxy, C1-6 alkyl, and C3-6 cycloalkyl; and R4, R5, R6, and R7 are each independently H, OH, OSO2CH3, O(CH2)mRe, CH2Rf, OCOCH2ORg, OCH2CH2ORg, OCH2CH?CHRg, or pyridine-2-yloxy, or R5 and R6 together form OCH2O.Type: GrantFiled: April 13, 2005Date of Patent: June 22, 2010Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Jang Hyuk Lee, Sun Chul Huh, Jae Mok Lee, Seog Beom Song, Soon Ji Kwon, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim
-
Patent number: 7728035Abstract: Compounds that may have anti-inflammatory activity are of general formula (I); wherein X1, is H or COR1, and X2 is H or COR2 but X1, and X2 are not both H; R1 and R2 are the same or different and are each C1-4 alkyl substituted with R3, or a four to seven-membered ring which can be optionally substituted with R8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR9; is R3 is F, CF3, OR4, NR5R6 O, S(O)n R7; R4, R5 and R6 are the same or different and are each H or C1-4 alkyl optionally substituted with R3, or NR5R6 is a C4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR8 and S(O)n; each n is 0-2; R7 is C1-4 alkyl; R8 is as defined for R3 or C1-4 alkyl optionally substituted with R3 or halogen; and R9 is H or C1-4 alkyl; or a salt, solvate or hydrate thereof.Type: GrantFiled: March 4, 2005Date of Patent: June 1, 2010Assignee: Sosei R&D Ltd.Inventors: Andrew Douglas Baxter, Andrea Walmsley
-
Patent number: 7728034Abstract: The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.Type: GrantFiled: January 5, 2006Date of Patent: June 1, 2010Assignee: Allergan, Inc.Inventors: George R. Ehring, Joseph S. Adorante, Larry A. Wheeler, Thomas Malone, Scott M. Whitcup
-
Publication number: 20100130438Abstract: A method for increasing oxytocin release through direct action on the epidermal keratinocytes is provided. The method for increasing oxytocin release in the epidermis includes increasing the calcium ion concentration in the epidermal cells. In the method of the present invention, the increase of the calcium ion concentration in the epidermal cells may be achieved by physically stimulating the skin. The physical stimulation may be achieved by applying a heat stimulus and/or a massage. The increase of the calcium ion concentration in the epidermal cells may be achieved by stimulating the epidermal cells by at least one agent selected from the group consisting of ATP, UTP, 4 alpha-phorbol 12,13-didecanoate, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 12, 2009Publication date: May 27, 2010Applicant: SHISEIDO COMPANY, LTD.Inventors: Sumiko Denda, Mitsuhiro Denda, Kazuyuki Ikeyama